MA

Mradul Agarwal

Active Director Director DIN 06596006
DIN 06596006 First appointment Jul 2013 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Jul 2013
Shareholding value •••• Premium profile

About Mradul Agarwal

Data last updated:

Mradul Agarwal is a Director at Ikon Pharmachem Private Limited (since 2013). The company operates in Pharma. Ikon Pharmachem Private Limited reported revenue of ₹19.51 Cr (FY 2024).

DIN 06596006
Primary Designation Director
Industry Pharma
First Appointment 02 Jul 2013
Oldest Company Age 13 yrs
Largest company Ikon Pharmachem Private Limited · ₹19.51 Cr (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Ikon Pharmachem Private Limited U93000UR2013PTC000769
Director02 Jul 20132013₹19.51 Cr (FY 2024)Active

Board colleagues of Mradul Agarwal

Directorship timeline

Open interactive timeline →
Ikon Pharmachem Private Limited
Premium access

Shareholding and investment profile for Mradul Agarwal

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Mradul Agarwal

Mradul Agarwal currently holds 1 directorship: Ikon Pharmachem Private Limited (Director, since 02 Jul 2013, revenue ₹19.51 Cr (FY 2024)).

Mradul Agarwal was first appointed on 02 Jul 2013 as Director at Ikon Pharmachem Private Limited.

The current boards of Mradul Agarwal's companies include Ashish Verma (Ikon Pharmachem Private Limited), Dinesh Panday (Ikon Pharmachem Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available